Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.
Alyssa M PeresleteMelissa E HughesAlyssa R MartinJanet FilesKyleen NguyenLauren BuckleyAshka PatelAbigail MooreEric P WinerDeborah DillonTianyu LiSara M TolaneyNancy U LinSarah L SammonsPublished in: Neuro-oncology (2024)
In this retrospective analysis, HER2 expression is common in breast cancer BrMs, emphasizing the need for improved, non-invasive diagnostics. Patients with HER2-low and HER2-0 BrMs face inferior survival, presenting an unmet clinical need.